Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effect of vildagliptin on copeptin in comparison to glimepiride, and whether copeptin could be used as a marker for the efficacy of vildagliptin in type 2 diabetes mellitus patients, and how copeptin correlates with other diabetic and cardiac markers.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Treatments: Glimepiride; Vildagliptin

Criteria

Inclusion criteria

• 70 uncontrolled adult patients with Type II-diabetes mellitus

Exclusion criteria

• Hepatic impairment.

• Active malignancy.

• Planned surgical intervention.

• Any signs of hypersensitivity or contraindication to study drugs developed.

• Addition of any anti-diabetic medications or insulin during follows up.

• Chronic inflammatory disease (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection).

• Pregnancy, lactation or child-bearing potential.

• Cardiac disease.

• Renal impairment.

• History of T1DM, SIAD, or diabetes insipidus.

• Therapy with any diuretic or a medication affecting the RAAS.